RxDoctor Payments Data

Victor Gordon, MD

Pulmonary Disease · Shelby Twp, MINPI 1346553781

Payments from drug & device makers

$1,976in general payments, 2019–2025

Across 83 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$311
  • Pulmonx Corporation$256
  • Jazz Pharmaceuticals Inc.$188
  • AstraZeneca$186
  • GSK$182
  • Boehringer Ingelheim$149
  • plus $703 from 14 others

What the payments were for

  • Food & beverage$1,976100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,976 in reported general payments places this provider in the 50th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$192,382
Medicare patients
654
Services billed
1,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter261$229,346
Spiriva RespimatTiotropium Bromide61$39,711
Combivent RespimatIpratropium/Albuterol Sulfate23$17,323
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$11,105
Breo ElliptaFluticasone/Vilanterol13$6,588
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$6,507
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,431
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$5,506
Ventolin HfaAlbuterol Sulfate69$4,777
Albuterol Sulfate HfaAlbuterol Sulfate129$4,234
SymbicortBudesonide/Formoterol Fumarate11$3,799
Montelukast Sodium16$271
Azithromycin26$191
Buspirone Hcl15$143
Prednisone90$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$182$242,365289 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat$149$57,03484 claims
AstraZenecaBreztri Aerosphere, Symbicort$186$14,90427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Shelby Twp

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →